Chirality-Dependent Tumor Phototherapy Using Amino Acid-Engineered Chiral Phosphorene

ACS Appl Mater Interfaces. 2023 Jan 11;15(1):651-661. doi: 10.1021/acsami.2c19291. Epub 2023 Jan 2.

Abstract

Phosphorene, also known as black phosphorus nanosheet (BPNS), has been investigated as a nanoagent for tumor therapy. However, promoting its intracellular accumulation while preventing the cytoplasmic decomposition remains challenging. Herein, for the first time, we propose a chiral BPNS designed through surface engineering based on amino acids with high biocompatibility and an abundant source for application in chirality-dependent tumor phototherapy based on its intracellular metabolism. The advantage of using cysteine (Cys) over other amino acids was that its d, l, or dl-form could efficiently work as the chirality inducer to modify the BPNS through electrostatic interaction and prevent alterations in the intrinsic properties of the BPNS. In particular, d-Cys-BPNS displayed an approximately threefold cytotoxic effect on tumor cells compared with l-Cys-BPNS, demonstrating a chirality-dependent therapy behavior. d-Cys-BPNS not only promoted high intracellular content but also showed resistance to cytoplasmic decomposition. Cys-engineered BPNS also demonstrated chirality-dependent phototherapy effects on tumor-bearing mice, in proximity to the results in vitro. Chiral engineering is expected to open new avenues that could promote the use of BPNS in tumor phototherapy and boost chiral nanomedicine.

Keywords: chiral nanomedicine; chirality-dependent tumor therapy; intracellular metabolism; phosphorene; surface engineering.

MeSH terms

  • Amino Acids* / chemistry
  • Animals
  • Antineoplastic Agents*
  • Cysteine / chemistry
  • Mice
  • Phototherapy

Substances

  • Amino Acids
  • Cysteine
  • Antineoplastic Agents